Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) shares saw unusually-strong trading volume on Monday . Approximately 158,252 shares changed hands during trading, an increase of 88% from the previous session’s volume of 84,029 shares.The stock last traded at $3.58 and had previously closed at $3.60.

Several analysts recently commented on AUPH shares. Leerink Swann reaffirmed an “outperform” rating and set a $7.00 price objective on shares of Aurinia Pharmaceuticals in a research note on Wednesday, July 6th. Canaccord Genuity set a $10.00 price target on Aurinia Pharmaceuticals and gave the company a “buy” rating in a research note on Friday. HC Wainwright assumed coverage on Aurinia Pharmaceuticals in a research note on Thursday, June 30th. They issued a “buy” rating and a $7.00 price target on the stock. Finally, Zacks Investment Research raised Aurinia Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, May 24th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Aurinia Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $7.15.

The stock’s market cap is $120.23 million. The stock’s 50 day moving average is $3.05 and its 200-day moving average is $2.73.

Aurinia Pharmaceuticals Inc (Aurinia) is a Canada-based is a clinical stage pharmaceutical company. The Company is focused on the development of its therapeutic immunomodulating drug candidate, voclosporin, which is a calcineurin inhibitor (CNI). Voclosporin is an oral drug, administered twice daily.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.